Get access
Powerful Medical
•
1. October 2024
•
1 min to read
  • Multicenter Clinical Investigation

Time for a Diagnostic Paradigm Shift From STEMI/​NSTEMI to OMI/​NOMI (DIFOCCULT-3)

Link to Publication

Summary

DIFOCCULT-3 is a randomized controlled study actively enrolling patients across 23 sites in Turkey. It evaluates AI-assisted ECG interpretation in detecting high-risk heart attack patterns. By comparing traditional STEMI/NSTEMI classification with an occlusion/non-occlusion model, the trial aims to improve acute coronary blockage detection. The primary composite endpoint includes all-cause mortality and all-cause re-hospitalization at 1-year follow-up, assessing its impact on long-term patient outcomes.

Study DesignRandomized Controlled Trial (RCT)
StatusEnrolling patients
Countries / Sites1 (Turkey) / 23
Study StartOctober 1, 2024
Primary Completion (estimated)October 1, 2025
Enrollment (target)5,000
clinicaltrials.gov ID NCT06570759

Link to Publication
Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is the market leader in AI-powered diagnostics, addressing the world’s leading cause of death – cardiovascular diseases. The innovative clinical assistant empowers healthcare professionals to detect up to 40 cardiovascular diseases. In the form of a smartphone application, the certified Class IIb medical device interprets any 12-lead ECG image in under 5 seconds to provide accurate diagnoses and individualized treatment recommendations tailored to each patient.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

All Publications
  • Associated Research, Study
  • Annals of Emergency Medicine
  • January 17, 2025

ECG Patterns of Occlusion Myocardial Infarction: a Narrative Review

This comprehensive review highlights the limitations of the traditional STEMI/NSTEMI classification for heart attacks and advocates for a more precise approach to diagnosis and patient triage. Instead of relying solely on standard ECG criteria, this method focuses on ECG patterns that more accurately reflect the severity of underlying coronary vessel disease. By identifying high-risk ECG changes beyond current STEMI guidelines, clinicians can detect heart attacks earlier, initiate treatment faster, and ultimately improve patient outcomes.
  • Abstract, Multicenter Clinical Investigation
  • JSCAI
  • January 13, 2025

Artificial Intelligence–Powered Electrocardiogram Detecting Culprit Vessel Blood Flow Abnormality: AI-ECG TIMI Study Design and Rationale

The AI-ECG TIMI study is a unique, multicenter registry currently enrolling patients to evaluate an AI-powered ECG model for detecting actively obstructed arteries in acute coronary syndrome (ACS). It is the first study to collect standard 12-lead ECGs precisely at the time of coronary angiography, providing novel insights into coronary occlusion and reperfusion. By identifying high-risk ECG patterns and assessing AI’s role in predicting intervention success, it paves the way for AI-driven precision cardiology in acute care.
More articles

Join 25,000 healthcare professionals who are already taking advantage of AI

Register now

Ready to get started?

Get access

Powerful Medical is redefining the landscape of medical diagnostics with its AI-driven solutions. The company’s certified PMcardio platform revolutionizes the way cardiovascular diseases are detected, offering rapid and accurate diagnostics that pave the way for timely and effective treatment.

Products

Company

Resources

Legal

Envelope Linkedin-in Instagram Facebook-f

© Powerful Medical 2025

Privacy

&

Cookies

Legal

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region. Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Sign up